Apolipoprotein

EZ-482 is an apolipoprotein (apoE) ligand that binds to the C-terminal domain of apoE3 and apoE4 through a unique N-terminal allosteric effect, useful in Alzheimer's disease research.

Anselamimab is a humanized IgG1κ monoclonal antibody targeting serum amyloid A1 (SAA1). It removes amyloid deposits by specifically binding to amyloid fibrils and triggering phagocytosis by macrophages and neutrophils.Anselamimab was used as an APP(β-amyloid A4 Protein Precursor ) inhibitor in the clinical phase for the treatment of light chain (AL) amyloidosis.

APL180 (L-4F) is an apolipoprotein A-I mimetic peptide that enhances the anti-inflammatory activity of high-density lipoprotein (HDL). It is applicable for cardiovascular disease research.

APOL1-IN-2 (Compound 467) acts as an inhibitor of apolipoprotein L1 (APOL1). It effectively reduces HEK293 cell death induced by APOL1 G2 G1, with EC50 values of 4.74 nM and 14.3 nM, respectively. Additionally, APOL1-IN-2 decreases the mortality of trypanosomes triggered by APOL1 G2 G1 G0, with EC50 values of 2.24, 6.03, and 3.72 nM, respectively.

APP-018 (D-4F) is an 18 D-amino acid peptide that mimics apolipoprotein A-I (apoA-I). It enhances the anti-inflammatory properties of high-density lipoprotein (HDL) and is applicable in cardiovascular disease research.